FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028361499> ?p ?o ?g. }

• W2028361499 endingPage "929" @default.
• W2028361499 startingPage "924" @default.
• W2028361499 abstract "Background: Vasculopathy is one of the hallmarks of systemic sclerosis (SSc), characterized by endothelial activation and over expression of adhesion molecules. A preliminary in vitro study has suggested that aminaftone, a naphtohydrochinone used in the treatment of capillary disorders, may downregulate the expression of adhesion molecules in endothelial cells. Objective: This study investigated the ex vivo effects of aminaftone on soluble adhesion molecule concentrations in patients with SSc. Methods: This randomized, open-label pilot study was conducted in patients with SSc. Patients received baseline treatment for Raynaud's phenomenon (eg, calcium channel blockers and IV cyclic iloprost) with (test) or without (control) aminaftone 75 mg or placebo TID for 12 weeks. Standard treatment for Raynaud's phenomenon was allowed as long as the dose was stable for ≥3 months prior to randomization. Concentrations of soluble E-selectin adhesion molecule 1 (sELAM-1), soluble vascular cell adhesion molecule 1 (sVCAM-1), and soluble intracellular adhesion molecule 1 (sICAM-1) were measured at baseline and 12 weeks, and their variation was tested using the analysis of variance for repeated measures with statistical correction. Laboratory analyses were performed by experienced personnel blinded to treatment assignment. Results: A total of 24 patients were enrolled (21 women, 3 men; mean age, 53.4 years; aminaftone, 12 patients; control, 12 patients). Decreases in mean (SD) sELAM-1 and sVCAM-1 concentrations were significantly greater in treated patients (sELAM-1, from 17.0 [7.8] to 11.9 [9.0] pg/mL; sVCAM-1, from 51.2 [12.9] to 40.8 [13.8] ng/mL) compared with controls (sELAM-1, from 20.3 [9.9] to 20.4 [10.5] pg/mL; sVCAM-1, from 56.8 [49.6] to 62.7 [40.6] ng/mL) (both, P < 0.05 [analysis of variance or repeated measures after Bonferroni correction]). No significant changes in sICAM-1 concentrations versus controls were observed. Conclusions: In this small pilot study in this select group of patients with SSc, aminaftone was associated with downregulation of sELAM-1 and sVCAM-1 concentrations. Studies evaluating the potential role of aminaftone in the treatment of vascular sclerodermal disease and SSc are warranted." @default.
• W2028361499 created "2016-06-24" @default.
• W2028361499 creator A5013119802 @default.
• W2028361499 creator A5020264713 @default.
• W2028361499 creator A5024770189 @default.
• W2028361499 creator A5050115769 @default.
• W2028361499 creator A5055847956 @default.
• W2028361499 creator A5085162857 @default.
• W2028361499 creator A5088524510 @default.
• W2028361499 creator A5079883060 @default.
• W2028361499 date "2008-05-01" @default.
• W2028361499 modified "2023-09-27" @default.
• W2028361499 title "Effects of aminaftone 75 mg TID on soluble adhesion molecules: A 12-week, randomized, open-label pilot study in patients with systemic sclerosis" @default.
• W2028361499 cites W1607729794 @default.
• W2028361499 cites W1981403699 @default.
• W2028361499 cites W1990354447 @default.
• W2028361499 cites W2028921539 @default.
• W2028361499 cites W2081741824 @default.
• W2028361499 cites W2102189463 @default.
• W2028361499 cites W2104276638 @default.
• W2028361499 cites W2113187512 @default.
• W2028361499 cites W2126910817 @default.
• W2028361499 cites W2161836280 @default.
• W2028361499 cites W2165386181 @default.
• W2028361499 doi "https://doi.org/10.1016/j.clinthera.2008.05.009" @default.
• W2028361499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18555939" @default.
• W2028361499 hasPublicationYear "2008" @default.
• W2028361499 type Work @default.
• W2028361499 sameAs 2028361499 @default.
• W2028361499 citedByCount "15" @default.
• W2028361499 countsByYear W20283614992014 @default.
• W2028361499 countsByYear W20283614992015 @default.
• W2028361499 countsByYear W20283614992016 @default.
• W2028361499 countsByYear W20283614992017 @default.
• W2028361499 countsByYear W20283614992019 @default.
• W2028361499 countsByYear W20283614992023 @default.
• W2028361499 crossrefType "journal-article" @default.
• W2028361499 hasAuthorship W2028361499A5013119802 @default.
• W2028361499 hasAuthorship W2028361499A5020264713 @default.
• W2028361499 hasAuthorship W2028361499A5024770189 @default.
• W2028361499 hasAuthorship W2028361499A5050115769 @default.
• W2028361499 hasAuthorship W2028361499A5055847956 @default.
• W2028361499 hasAuthorship W2028361499A5079883060 @default.
• W2028361499 hasAuthorship W2028361499A5085162857 @default.
• W2028361499 hasAuthorship W2028361499A5088524510 @default.
• W2028361499 hasConcept C126322002 @default.
• W2028361499 hasConcept C132155493 @default.
• W2028361499 hasConcept C142724271 @default.
• W2028361499 hasConcept C150903083 @default.
• W2028361499 hasConcept C16224149 @default.
• W2028361499 hasConcept C168563851 @default.
• W2028361499 hasConcept C178790620 @default.
• W2028361499 hasConcept C185592680 @default.
• W2028361499 hasConcept C203014093 @default.
• W2028361499 hasConcept C204243189 @default.
• W2028361499 hasConcept C204787440 @default.
• W2028361499 hasConcept C207001950 @default.
• W2028361499 hasConcept C26291073 @default.
• W2028361499 hasConcept C27081682 @default.
• W2028361499 hasConcept C2776246508 @default.
• W2028361499 hasConcept C2776992346 @default.
• W2028361499 hasConcept C71924100 @default.
• W2028361499 hasConcept C84416704 @default.
• W2028361499 hasConcept C85789140 @default.
• W2028361499 hasConcept C86803240 @default.
• W2028361499 hasConcept C90924648 @default.
• W2028361499 hasConceptScore W2028361499C126322002 @default.
• W2028361499 hasConceptScore W2028361499C132155493 @default.
• W2028361499 hasConceptScore W2028361499C142724271 @default.
• W2028361499 hasConceptScore W2028361499C150903083 @default.
• W2028361499 hasConceptScore W2028361499C16224149 @default.
• W2028361499 hasConceptScore W2028361499C168563851 @default.
• W2028361499 hasConceptScore W2028361499C178790620 @default.
• W2028361499 hasConceptScore W2028361499C185592680 @default.
• W2028361499 hasConceptScore W2028361499C203014093 @default.
• W2028361499 hasConceptScore W2028361499C204243189 @default.
• W2028361499 hasConceptScore W2028361499C204787440 @default.
• W2028361499 hasConceptScore W2028361499C207001950 @default.
• W2028361499 hasConceptScore W2028361499C26291073 @default.
• W2028361499 hasConceptScore W2028361499C27081682 @default.
• W2028361499 hasConceptScore W2028361499C2776246508 @default.
• W2028361499 hasConceptScore W2028361499C2776992346 @default.
• W2028361499 hasConceptScore W2028361499C71924100 @default.
• W2028361499 hasConceptScore W2028361499C84416704 @default.
• W2028361499 hasConceptScore W2028361499C85789140 @default.
• W2028361499 hasConceptScore W2028361499C86803240 @default.
• W2028361499 hasConceptScore W2028361499C90924648 @default.
• W2028361499 hasIssue "5" @default.
• W2028361499 hasLocation W20283614991 @default.
• W2028361499 hasLocation W20283614992 @default.
• W2028361499 hasOpenAccess W2028361499 @default.
• W2028361499 hasPrimaryLocation W20283614991 @default.
• W2028361499 hasRelatedWork W2000506015 @default.
• W2028361499 hasRelatedWork W2052316327 @default.
• W2028361499 hasRelatedWork W2054096510 @default.
• W2028361499 hasRelatedWork W2066503447 @default.
• W2028361499 hasRelatedWork W2097492202 @default.
• W2028361499 hasRelatedWork W2139921261 @default.

• next